This manuscript describes the activities of a novel oral S1P1 agonist (AKP-11) with therapeutic efficacy similar to the one observed with FDA approved oral drug FTY720 in an animal model of MS but with a better safety profile as compared with FTY720. Here, S1PR1 is linked to myeloid sarcoma.